Changes in Beneficial Ownership · 4
Atea Pharmaceuticals, Inc.
AVIRNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-18
- Issuer
- Atea Pharmaceuticals, Inc.
- Issuer CIK
- 0001593899
- Trading symbol
- AVIR
Reporting owner 1
- Name
- Berman Howard
- Reporting owner CIK
- 0001952986
- Relationship
- Director
- Address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F1] | 2026-06-18 | A · Form 4 | 26,700 | A | 0 | [F2] | [F2] | Common Stock | 26,700 | 26,700 | D |
| Stock Option (Right to Buy) | 4.36 | 2026-06-18 | A · Form 4 | 37,700 | A | 0 | [F3] | 2036-06-17 | Common Stock | 37,700 | 37,700 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.↩ 1
- F2
- The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.↩ 1↩ 2
- F3
- The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Andrea Corcoran, as Attorney-in-Fact for Howard Berman
- Date
- 2026-06-23
Company context
Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat ssRNA viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s Phase 3 program is evaluating the FDC regimen of BEM, a nucleotide analog polymerase inhibitor, and RZR, an NS5A inhibitor, to treat HCV. AT-587, a nucleotide analog, is in Phase 1 development for the treatment of HEV. For more information, please visit www.ateapharma.com.